Literature DB >> 18073428

The evolution of two mutations during clonal expansion.

Hiroshi Haeno1, Yoh Iwasa, Franziska Michor.   

Abstract

Knudson's two-hit hypothesis proposes that two genetic changes in the RB1 gene are the rate-limiting steps of retinoblastoma. In the inherited form of this childhood eye cancer, only one mutation emerges during somatic cell divisions while in sporadic cases, both alleles of RB1 are inactivated in the growing retina. Sporadic retinoblastoma serves as an example of a situation in which two mutations are accumulated during clonal expansion of a cell population. Other examples include evolution of resistance against anticancer combination therapy and inactivation of both alleles of a metastasis-suppressor gene during tumor growth. In this article, we consider an exponentially growing population of cells that must evolve two mutations to (i) evade treatment, (ii) make a step toward (invasive) cancer, or (iii) display a disease phenotype. We calculate the probability that the population has evolved both mutations before it reaches a certain size. This probability depends on the rates at which the two mutations arise; the growth and death rates of cells carrying none, one, or both mutations; and the size the cell population reaches. Further, we develop a formula for the expected number of cells carrying both mutations when the final population size is reached. Our theory establishes an understanding of the dynamics of two mutations during clonal expansion.

Entities:  

Mesh:

Year:  2007        PMID: 18073428      PMCID: PMC2219486          DOI: 10.1534/genetics.107.078915

Source DB:  PubMed          Journal:  Genetics        ISSN: 0016-6731            Impact factor:   4.562


  31 in total

1.  Evolution of resistance during clonal expansion.

Authors:  Yoh Iwasa; Martin A Nowak; Franziska Michor
Journal:  Genetics       Date:  2006-04       Impact factor: 4.562

Review 2.  Mechanisms of cancer drug resistance.

Authors:  Michael M Gottesman
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

3.  The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.

Authors:  John S Tokarski; John A Newitt; Chieh Ying J Chang; Janet D Cheng; Michael Wittekind; Susan E Kiefer; Kevin Kish; Francis Y F Lee; Robert Borzillerri; Louis J Lombardo; Dianlin Xie; Yaqun Zhang; Herbert E Klei
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

Review 4.  Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia.

Authors:  T L Holyoake; X Jiang; M W Drummond; A C Eaves; C J Eaves
Journal:  Leukemia       Date:  2002-04       Impact factor: 11.528

5.  p53 status and the efficacy of cancer therapy in vivo.

Authors:  S W Lowe; S Bodis; A McClatchey; L Remington; H E Ruley; D E Fisher; D E Housman; T Jacks
Journal:  Science       Date:  1994-11-04       Impact factor: 47.728

6.  Somatic mosaicism and cancer: inference based on a conditional Luria-Delbrück distribution.

Authors:  Steven A Frank
Journal:  J Theor Biol       Date:  2003-08-21       Impact factor: 2.691

7.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

Review 8.  Dissemination and growth of cancer cells in metastatic sites.

Authors:  Ann F Chambers; Alan C Groom; Ian C MacDonald
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

9.  Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.

Authors:  Neil P Shah; Brian J Skaggs; Susan Branford; Timothy P Hughes; John M Nicoll; Ronald L Paquette; Charles L Sawyers
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

10.  A two-stage theory of carcinogenesis in relation to the age distribution of human cancer.

Authors:  P ARMITAGE; R DOLL
Journal:  Br J Cancer       Date:  1957-06       Impact factor: 7.640

View more
  32 in total

Review 1.  Evolution of acquired resistance to anti-cancer therapy.

Authors:  Jasmine Foo; Franziska Michor
Journal:  J Theor Biol       Date:  2014-03-25       Impact factor: 2.691

2.  Dynamics of targeted cancer therapy.

Authors:  Ivana Bozic; Benjamin Allen; Martin A Nowak
Journal:  Trends Mol Med       Date:  2012-05-15       Impact factor: 11.951

3.  Accumulation of driver and passenger mutations during tumor progression.

Authors:  Ivana Bozic; Tibor Antal; Hisashi Ohtsuki; Hannah Carter; Dewey Kim; Sining Chen; Rachel Karchin; Kenneth W Kinzler; Bert Vogelstein; Martin A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-27       Impact factor: 11.205

4.  Evolutionary dynamics of tumor progression with random fitness values.

Authors:  Rick Durrett; Jasmine Foo; Kevin Leder; John Mayberry; Franziska Michor
Journal:  Theor Popul Biol       Date:  2010-05-19       Impact factor: 1.570

Review 5.  The challenge of drug resistance in cancer treatment: a current overview.

Authors:  Michail Nikolaou; Athanasia Pavlopoulou; Alexandros G Georgakilas; Efthymios Kyrodimos
Journal:  Clin Exp Metastasis       Date:  2018-05-24       Impact factor: 5.150

6.  Impact of deleterious passenger mutations on cancer progression.

Authors:  Christopher D McFarland; Kirill S Korolev; Gregory V Kryukov; Shamil R Sunyaev; Leonid A Mirny
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-06       Impact factor: 11.205

7.  Evolution of resistance to anti-cancer therapy during general dosing schedules.

Authors:  Jasmine Foo; Franziska Michor
Journal:  J Theor Biol       Date:  2009-12-11       Impact factor: 2.691

8.  POPULATION GENETICS OF NEUTRAL MUTATIONS IN EXPONENTIALLY GROWING CANCER CELL POPULATIONS.

Authors:  Rick Durrett
Journal:  Ann Appl Probab       Date:  2013       Impact factor: 1.872

Review 9.  The mathematics of cancer: integrating quantitative models.

Authors:  Philipp M Altrock; Lin L Liu; Franziska Michor
Journal:  Nat Rev Cancer       Date:  2015-12       Impact factor: 60.716

10.  Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies.

Authors:  Jasmine Foo; Franziska Michor
Journal:  PLoS Comput Biol       Date:  2009-11-06       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.